Published in Nat Med on October 14, 2007
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med (2008) 5.62
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Systemic inflammation and disease progression in Alzheimer disease. Neurology (2009) 3.79
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Regulation of innate immune responses in the brain. Nat Rev Immunol (2009) 3.41
Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol (2009) 2.86
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 2.78
Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc Natl Acad Sci U S A (2013) 2.45
A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol (2010) 2.42
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One (2011) 2.30
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 2.23
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol (2013) 1.99
Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry (2008) 1.93
Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement (2014) 1.85
Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis (2010) 1.73
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol (2012) 1.66
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One (2010) 1.62
Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany NY) (2012) 1.61
MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders. Curr Genomics (2009) 1.60
Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol (2010) 1.59
Systematic analysis, comparison, and integration of disease based human genetic association data and mouse genetic phenotypic information. BMC Med Genomics (2010) 1.57
A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One (2011) 1.55
Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol (2010) 1.52
Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One (2012) 1.51
How do immune cells support and shape the brain in health, disease, and aging? J Neurosci (2013) 1.51
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med (2008) 1.48
Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 1.44
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener (2016) 1.41
The immunology of neurodegeneration. J Clin Invest (2012) 1.41
Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. PLoS One (2010) 1.41
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation (2010) 1.40
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.39
Inflammatory Stress on Autophagy in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease during 24 Months of Follow-Up. PLoS One (2015) 1.39
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.38
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging (2008) 1.35
Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis (2010) 1.33
Metabolome in progression to Alzheimer's disease. Transl Psychiatry (2011) 1.33
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One (2011) 1.32
Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study. BMC Neurol (2010) 1.32
Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS One (2008) 1.31
Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J Exp Med (2013) 1.27
The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol (2010) 1.26
Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25
Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology (2010) 1.24
Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med (2010) 1.24
Circulating miRNA biomarkers for Alzheimer's disease. PLoS One (2013) 1.22
AKI in hospitalized children: epidemiology and clinical associations in a national cohort. Clin J Am Soc Nephrol (2013) 1.22
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21
A self-powered, one-step chip for rapid, quantitative and multiplexed detection of proteins from pinpricks of whole blood. Lab Chip (2010) 1.18
On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nat Med (2012) 1.17
Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol J (2009) 1.15
Circulating cytokines as biomarkers of alcohol abuse and alcoholism. J Neuroimmune Pharmacol (2009) 1.15
A computational analysis of protein-protein interaction networks in neurodegenerative diseases. BMC Syst Biol (2008) 1.14
A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord (2011) 1.14
Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J Neurosci (2013) 1.14
Multiplexed volumetric bar-chart chip for point-of-care diagnostics. Nat Commun (2012) 1.13
Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol Aging (2012) 1.13
Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med (2010) 1.12
Genes and pathways underlying regional and cell type changes in Alzheimer's disease. Genome Med (2013) 1.12
Biomarkers in translational research of Alzheimer's disease. Neuropharmacology (2010) 1.11
APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One (2010) 1.11
Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis (2009) 1.10
Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One (2012) 1.09
Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis (2013) 1.08
Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One (2011) 1.07
Analysis of sampling techniques for imbalanced data: An n = 648 ADNI study. Neuroimage (2013) 1.06
Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement (2014) 1.06
Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One (2011) 1.06
TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects. J Neuroimmunol (2009) 1.05
Development of fluorescent polymerization-based signal amplification for sensitive and non-enzymatic biodetection in antibody microarrays. Acta Biomater (2009) 1.05
Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J Clin Invest (2013) 1.05
Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. Hum Mol Genet (2015) 1.05
Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol (2011) 1.04
Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front Cell Neurosci (2013) 1.04
Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer (2009) 1.04
Iron and the immune system. J Neural Transm (Vienna) (2010) 1.03
A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry (2013) 1.03
Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry (2014) 1.03
Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst) (2016) 1.02
Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease. Alzheimers Res Ther (2012) 1.02
Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy. Neuroscience (2014) 1.01
Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis (2008) 1.01
Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta (2008) 1.01
Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res Ther (2009) 1.00
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis (2010) 1.00
Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med (2008) 0.98
Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol (2014) 0.98
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Sparse inverse covariance estimation with the graphical lasso. Biostatistics (2007) 24.38
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Empirical bayes methods and false discovery rates for microarrays. Genet Epidemiol (2002) 10.56
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med (2004) 9.81
Neurodegenerative diseases target large-scale human brain networks. Neuron (2009) 9.69
A penalized matrix decomposition, with applications to sparse principal components and canonical correlation analysis. Biostatistics (2009) 9.40
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature (2005) 8.55
Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol (2004) 7.68
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet (2006) 5.34
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry (2006) 5.30
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Cell type-specific gene expression differences in complex tissues. Nat Methods (2010) 4.75
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology (2010) 4.61
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol (2003) 4.28
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med (2003) 4.20
Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol (2008) 4.15
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest (2008) 4.09
Defining mild cognitive impairment in Parkinson's disease. Mov Disord (2007) 3.92
Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature (2007) 3.92
Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain (2010) 3.84
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry (2010) 3.66
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol (2003) 3.66
Regularized linear discriminant analysis and its application in microarrays. Biostatistics (2006) 3.66
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest (2006) 3.51
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature (2008) 3.48
A framework for feature selection in clustering. J Am Stat Assoc (2010) 3.46
Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data. Stat Methods Med Res (2011) 3.44
Covariance-regularized regression and classification for high-dimensional problems. J R Stat Soc Series B Stat Methodol (2009) 3.31
Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol (2014) 3.29
Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol (2003) 3.20
Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology (2005) 3.14
Identification of a central role for complement in osteoarthritis. Nat Med (2011) 3.11
Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol (2005) 3.11
Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron (2012) 3.07
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol (2008) 3.03
Rapidly progressive dementia. Ann Neurol (2008) 3.00
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
Neuroanatomical correlates of behavioural disorders in dementia. Brain (2005) 2.92
Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol (2002) 2.87
A network model of a cooperative genetic landscape in brain tumors. JAMA (2009) 2.86
A method for calling gains and losses in array CGH data. Biostatistics (2005) 2.86
Genome-wide measurement of RNA folding energies. Mol Cell (2012) 2.85
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci (2009) 2.82
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol (2006) 2.79